Candriam Luxembourg S.C.A. Lowers Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Candriam Luxembourg S.C.A. lowered its holdings in Revolution Medicines, Inc. (NASDAQ:RVMDGet Rating) by 8.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 450,382 shares of the company’s stock after selling 39,000 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Revolution Medicines were worth $11,336,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada bought a new position in shares of Revolution Medicines during the 3rd quarter valued at about $48,000. First Mercantile Trust Co. increased its position in shares of Revolution Medicines by 23.3% during the 3rd quarter. First Mercantile Trust Co. now owns 1,853 shares of the company’s stock valued at $51,000 after purchasing an additional 350 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Revolution Medicines during the 3rd quarter valued at about $114,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Revolution Medicines by 34.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,743 shares of the company’s stock valued at $170,000 after purchasing an additional 1,744 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new position in shares of Revolution Medicines during the 3rd quarter valued at about $208,000.

Several equities analysts have recently commented on the company. SVB Leerink reiterated an “outperform” rating on shares of Revolution Medicines in a research report on Monday, May 9th. Stifel Nicolaus upgraded Revolution Medicines from a “hold” rating to a “buy” rating and reduced their price target for the stock from $36.00 to $26.00 in a research report on Tuesday, March 1st. HC Wainwright raised their price target on Revolution Medicines from $38.00 to $40.00 in a research report on Tuesday, March 1st. Finally, Zacks Investment Research upgraded Revolution Medicines from a “sell” rating to a “hold” rating in a research report on Saturday, April 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $33.00.

Shares of RVMD stock opened at $16.53 on Wednesday. Revolution Medicines, Inc. has a fifty-two week low of $14.08 and a fifty-two week high of $35.07. The business’s 50 day moving average price is $21.61 and its 200-day moving average price is $23.74.

Revolution Medicines (NASDAQ:RVMDGet Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04. Revolution Medicines had a negative return on equity of 33.52% and a negative net margin of 773.42%. During the same period last year, the company posted ($0.53) EPS. Research analysts forecast that Revolution Medicines, Inc. will post -3.58 earnings per share for the current year.

In other Revolution Medicines news, Director Thilo Schroeder acquired 3,110 shares of the business’s stock in a transaction dated Friday, March 11th. The shares were purchased at an average cost of $20.93 per share, for a total transaction of $65,092.30. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders bought 972,079 shares of company stock worth $18,310,981. Corporate insiders own 22.60% of the company’s stock.

Revolution Medicines Profile (Get Rating)

Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.

Featured Stories

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMDGet Rating).

Institutional Ownership by Quarter for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.